WuXi Biologics
WuXi Biologics
WuXi Biologics WuXi AppTec is expected to provide world-class integrated biopharmace
WuXi Biologics is a subsidiary of the WuXi AppTec Group with branches in Wuxi, Shanghai and Suzhou. As a platform for innovative companies to realize their dream of developing new drugs, WuXi AppTec is expected to provide world-class integrated biopharmaceutical R&D and manufacturing services to more innovative biotech companies at home and abroad in the future, accelerating the process of bringing innovative biopharmaceuticals to market in China for the benefit of patients.
- All
- News
- Analysis
- Research
Briefing Yesterday 11:57 AM
· Healthcare
Triarm therapeutics completed a round of financing of US $60 million
Briefing Sep 18, 2021 09:08 AM
· Healthcare
Puri benchmark obtained 150 million yuan of round B financing to promote the research and development of new drugs driven by multi omics data mining
In depth
Healthcare
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
Briefing Sep 13, 2021 02:15 PM
· Healthcare
Baiji Shenzhou welcomes the milestone of "going to sea" again, and PD-1 monoclonal antibody baizean ® The new drug marketing application for esophageal squamous cell carcinoma was accepted by FDA
Briefing Sep 03, 2021 05:42 PM
· Healthcare
Nuocheng Jianhua and kangnoah deepen strategic cooperation and develop first in class macromolecular innovative drugs
Apr 22, 2021 03:11 PM
Research
Technology, Consumer Staples, HealthcareWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Industrials, Financials, AutomotiveTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Sep 03, 2021 09:45 AM
· Healthcare
Yao Ming Ju Nuo Rui Qi orenzai was approved as the second car-t product in China
Briefing Sep 03, 2021 09:38 AM
· Healthcare
Baiji Shenzhou zebutinib new indications approved by FDA
Briefing Sep 03, 2021 09:18 AM
· Healthcare
China's first generic drug of sitagliptin using biosynthesis technology was approved
Insight
Briefing Sep 02, 2021 02:26 PM
· Healthcare
Xinda biology and JinFang medicine have reached global strategic cooperation on KRAS G12C inhibitor gfh925
Briefing Aug 30, 2021 01:46 PM
· Healthcare
PD-1 jointly developed by Yuheng pharmaceutical and Yaoming biology was approved for listing
Briefing Jul 21, 2021 03:11 PM
The latest position of Qu Yang, fund manager of Qianhai open source: Hong Kong stocks redistributed, Tencent holdings and BYD holdings increased
Insight
Healthcare
Genetron Health's Self-Developed Mutation Capsule Differentiates It from Others
Since the outbreak of COVID-19, new public health systems and advanced biotechnology have been swiftly hyped up. Genetron Health has been able to generate a surging revenue in these special social circumstances.
May 26, 2021 05:17 AM
Healthcare
Sinopharm COVID Vaccine Receives WHO Emergency Use Certification
The Sinopharm Group’s COVID Vaccine is the sixth vaccine to receive safety, efficacy and quality verification from the World Health Organization (WHO). It is the first vaccine from a non-Western country to receive WHO certification.
May 11, 2021 03:35 AM
Briefing Jul 21, 2021 08:05 AM
· Healthcare
Notice: the National Health Commission will hold a press conference on China's hierarchical diagnosis and treatment system and system construction
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- More Room for the Medical Device Market to Grow in China
- Tong Ren Tang: Any Hope for this Purveyor of Centuries-Old Chinese Medicines?
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.